NCT03522259.

Study name	Rivaroxaban as thrombosis prophylaxis in bariatric surgery (BARIVA)
Methods	Single‐centre, open‐label, 2‐arm, parallel‐group RCT
Participants	People with scheduled elective bariatric surgery or redo surgery after bariatric interventions, both sexes, aged ≥ 18 years
Interventions	Experimental: rivaroxaban 10 mg started on the first postoperative day and continued for 28 days after surgery Control: rivaroxaban 10 mg started on the first postoperative day and continued for 7 days after surgery
Outcomes	Primary outcomes Number of participants with symptomatic or asymptomatic VTE (28 days), assessed by ultrasound Secondary outcomes Number of participants with symptomatic VTE within 28 days after bariatric surgery, assessed by ultrasound Number of participants with asymptomatic VTE within 28 days after bariatric surgery, assessed by ultrasound All‐cause mortality within 28 days after bariatric surgery
Starting date	19 July 2018
Contact information	Guido Stirnimann, MD, +41 31 632 21 11, guido.stirnimann@insel.ch
Notes	NCT03522259